Foamix Pharmaceuticals Ltd (FOMX) Receives Average Recommendation of “Hold” from Analysts

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has received an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $17.00.

Several equities research analysts have commented on FOMX shares. Cowen set a $30.00 price target on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $15.00 price target on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 7th. Finally, ValuEngine cut shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th.

FOMX stock traded up $0.03 during trading on Friday, hitting $2.49. The company had a trading volume of 178,614 shares, compared to its average volume of 336,176. The company has a market capitalization of $138.25 million, a P/E ratio of -1.46 and a beta of 1.60. Foamix Pharmaceuticals has a fifty-two week low of $2.40 and a fifty-two week high of $7.60.



Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its quarterly earnings data on Thursday, February 28th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $0.95 million. Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 79.46%. On average, sell-side analysts expect that Foamix Pharmaceuticals will post -1.59 EPS for the current fiscal year.

In other Foamix Pharmaceuticals news, Director Anna Kazanchyan sold 10,600 shares of the business’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $2.61, for a total transaction of $27,666.00. Following the sale, the director now owns 55,955 shares in the company, valued at approximately $146,042.55. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Matthew T. Wiley acquired 13,440 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were bought at an average price of $3.76 per share, for a total transaction of $50,534.40. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 19,911 shares of company stock worth $62,582. Corporate insiders own 2.95% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of FOMX. Bank of New York Mellon Corp boosted its position in Foamix Pharmaceuticals by 26.9% during the third quarter. Bank of New York Mellon Corp now owns 636,127 shares of the specialty pharmaceutical company’s stock worth $3,645,000 after acquiring an additional 134,676 shares during the last quarter. ETF Managers Group LLC boosted its position in Foamix Pharmaceuticals by 66.6% during the fourth quarter. ETF Managers Group LLC now owns 81,972 shares of the specialty pharmaceutical company’s stock worth $294,000 after acquiring an additional 32,773 shares during the last quarter. BlackRock Inc. boosted its position in Foamix Pharmaceuticals by 29.7% during the fourth quarter. BlackRock Inc. now owns 620,816 shares of the specialty pharmaceutical company’s stock worth $2,229,000 after acquiring an additional 142,159 shares during the last quarter. Van ECK Associates Corp boosted its position in Foamix Pharmaceuticals by 75.1% during the fourth quarter. Van ECK Associates Corp now owns 19,752 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 8,474 shares during the last quarter. Finally, Knott David M acquired a new position in Foamix Pharmaceuticals during the fourth quarter worth about $740,000. Hedge funds and other institutional investors own 53.14% of the company’s stock.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

Recommended Story: Net Income

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.